Ionis Pharmaceuticals, Inc. Investigation
Company: Ionis Pharmaceuticals, Inc.
Ticker: (NASDAQ) IONS
See If You Qualify For Monetary Reward
Join the Ionis Pharmaceuticals, Inc. Investigation
Investigation Details
Ionis Pharmaceuticals shares were falling more than 20% on July 9, 2026, after the Company disclosed that its Phase-3 CARDIO-TTRansform trial failed to meet its primary endpoint.
The investigation concerns whether the Company's prior public statements regarding the CARDIO-TTRansform program aligned with the trial's ultimate outcome. On November 6, 2024, CEO Brett Monia stated on the Company's Q3 2024 earnings call that the "ongoing CARDIO-TTRansform trial [was] on track to deliver the most comprehensive dataset in these patients in the second half of 2026." More recently, on June 10, 2026, CEO Monia reiterating that data was expected in the back half of the year, told investors “everything is going very well in the conduct of the study and the execution. The study is reasonably derisked for its primary endpoint. We’re excited.”
On July 9, 2026, the company disclosed that its trial, partnered with AstraZeneca, did not meet its primary endpoint of reducing combined cardiovascular death and recurrent events in transthyretin-mediated amyloid cardiomyopathy patients. The stock opened down more than 20% on the news.